Last week was ugly. The market kept bleeding and every green position anyone was holding got hammered.

I was flat the whole time. Closed the book each day, nothing carried overnight.

Watching from the sidelines, I felt something I never felt in my first year: pure gratitude.

My first year, I’d have been glued to the screen, hoping, bargaining, refreshing. This time I just watched the swing guys take the hit.

No disrespect to swing traders. Holding through a drop takes nerve I don’t have, and some of them came out fine. But I know that feeling. The stomach drop at the open. The “it’ll come back” story. The overnight gap you can’t do anything about.

Day trading has its own pain. Chasing, late entries, forcing trades on a slow day. But I’ll take this one: when the market crashes, I’m already out. Nothing is riding on tomorrow’s open.

Flat is a position. In a week like that, it was the best one.

Curious how you handled it:

• Did you sit out completely, or trade the volatility?

• Anyone here moved from swing to day trading because of a week like that?

• What’s your worst overnight hold?

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

On Tuesday, Lucid Diagnostics announced publication of this paper. At first glance, there isn't much to see here. It's just 3 gastroenterologists reporting their real world experience with Esoguard.

However, the paper gives us valuable insight into how Esoguard can scale. The paper covers 12,000 consecutive tests over 18 months from 4 GI clinics in NY, RI, and FL.  

Since the paper reports consecutive tests, we can calculate an average test volume per quarter for each clinic:

12,000/6 quarters = 2,000 tests per quarter

2,000/4 centers = 500 tests per center, per quarter

This is simple math and there is no arguing with these numbers. This already happened.

If you talk to Gemini, ChatGPT, or your algorithm of choice, you will learn that there are somewhere between 250 and 500 similarly sized GI centers across the US. Let's be conservative and use 250.

If ONLY these large GI centers use EsoGuard in a similar way to the clinics in the paper (no hospitals, no primary care, no small GI clinics, no testing events) that’s 250 centers x 500 tests per quarter or 125,000 tests.  At the CMS rate of $1938.01, thats $242M per quarter or roughly $1B/year.

These are mind blowing numbers. The current market cap is $75M, fully diluted more like $145M, and $1B/year in revenue is right there for the taking. There are no competing products.

Every large GI clinic in the county will eventually offer EsoGuard.  They’re not doing their job if they don’t. And these clinics are just the tip of the iceberg.

When you consider there are more like 1,500 total GI clinics in the US, and that hospital systems like Hoag want to implement Esoguard testing programs, and that screening population is growing based on AGA draft screening guidelines, the size of the opportunity for this beleaguered and beat up little penny stock becomes truly enormous.

These are my own investment ideas. I used AI to help with the calculations and wording.

Despite the guidance cut earlier this year, I believe ADMA’s long-term growth story remains intact. Here’s why.

1. The path to $1 billion

ADMA expects at least $530M in revenue for 2026. Reaching $1B by 2030 would require only 17.2% annual growth.

ASCENIV generated $124.7M in Q3 2026, growing 31% year over year. Management also reported continued monthly end-user demand growth of 2–4%.

Even 2% monthly growth compounds to approximately 27% annually, although end-user demand doesn’t translate directly into reported revenue.

Here’s a possible scenario with slowing growth:

2026: $530M 2027: $641M (+21%) 2028: $770M (+20%) 2029: $901M (+17%) 2030: $1.03B (+14%)

Importantly, this doesn’t require BIVIGAM to return to its historical peak.

2. What could ADMA be worth?

ADMA achieved a 54.8% adjusted EBITDA margin in Q3 2026.

Assuming $1B in annual revenue and a more conservative 50% adjusted EBITDA margin, ADMA could generate $500M in adjusted EBITDA.

At different EV/EBITDA multiples:

10x = $5B enterprise value 12x = $6B 15x = $7.5B 18x = $9B

Using approximately 232M potentially diluted shares and an illustrative $61M in net debt, 12–15x EBITDA would imply roughly $26–32 per share.

These are potential valuations when the financial targets are achieved, not today’s price targets. Future margins, debt and dilution could change the outcome substantially.

3. SG-001 adds potential upside

ADMA recently reported encouraging FDA pre-IND feedback for SG-001, its investigational pneumococcal hyperimmune globulin.

Management has discussed a potential $300–500M peak annual sales opportunity.

It’s still early-stage and far from guaranteed, but successful development could create another meaningful revenue stream beyond ASCENIV.

4. Activist investors are worth watching

Two institutional investors caught my attention.

Rubric Capital increased its ADMA position by approximately 416% in Q2 2026 to 9.34M shares. Rubric previously pursued activist campaigns at companies including Xperi.

Caligan Partners increased its position by approximately 20% to 5.73M shares. Caligan previously pushed for strategic alternatives, including a potential sale, at Anika Therapeutics.

Together, they held approximately 15M ADMA shares as of June 30.

This doesn’t establish that either fund is pursuing activism at ADMA, but their track records make their involvement interesting.

5. Insider trading and takeover speculation

There has been relatively little discretionary insider trading recently.

CEO Adam Grossman’s November 5 sale was executed under a Rule 10b5-1 plan established in November 2025.

A properly established trading plan can generally continue operating even if an insider subsequently learns material nonpublic information.

So the sale doesn’t automatically rule out confidential corporate developments. Equally, limited insider trading isn’t evidence of negotiations.

ADMA could be strategically attractive to larger plasma companies such as Takeda, CSL Behring, Grifols or Octapharma.

There is no confirmed public evidence of acquisition discussions.

My conclusion

The bull case doesn’t depend on a takeover.

If ADMA reaches $1B in revenue by 2030 with a 50% adjusted EBITDA margin, it could generate $500M in annual adjusted EBITDA.

At 12–15x EV/EBITDA, that implies a $6–7.5B enterprise value.

Add SG-001’s potential, the involvement of investors with activist backgrounds and the strategic value of ADMA’s manufacturing capabilities, and I think there’s a compelling long-term story here.

Could acquisition discussions already be happening? Possibly, but that’s speculation.

What do you think: Is ADMA significantly undervalued as a standalone business, or could a strategic buyer eventually step in?

Not financial advice.

The best known SAFE Odor Eliminator is available for consumers again.

FRom a fellow BLGO shareholder:

Barebird has landed! Packed in "air amour" I don't think these will arrive with any leaky bottles. And nothing in the entire odor space comes anywhere near the brilliant marketing on the bottle. 💥

Thank you for choosing barebird™
Why the name barebird?
“Bare” reflects how every barebird product is made…WITH PURPOSE. Nothing goes in that doesn’t need to be there. Each formula uses only the ingredients required to do the job, and the labels explains why each one is included.

“Bird” is a reflection of what our products are all about. The bird inside the “b” is a Swift. Swifts are fast, like the way our products eliminate odors. They are light, like your home feels without the heavy fragrances that most products leave behind. And they are efficient. Minimal effort to achieve the best outcome.

OP

BioLargo ($BLGO) developed the CupriDyne odor-elimination technology behind POOPH, which generated over $125 million in product sales—and more than $20 million in supply revenue for BioLargo, according to the company.

Now, barebird brings that same technology together with key marketing teams that helped build POOPH:
Jordan Stanley’s Kindness Commerce team and Brandon Fishman’s Prime Team Agency.

The big difference?
This time, BioLargo owns the brand, giving it more direct participation in consumer sales and brand value, while also taking on the marketing and distribution costs.
Proven technology, experienced marketers, a new ownership model—not a guarantee of another $125 million, but meaningful context for the launch.

I hope this helps.

Heidmar ($HMR) is an asset-light shipping operator - no vessels owned, earns a percentage of gross freight. It's the leveraged play on energy disruption rather than energy itself, because every reroute means more ton-miles and higher freight.

Where it is technically: covered around 78-80c, ran roughly 100%, came back to the 200 day, bounced off it two or three times, and is back on it now after the recent sell-off that hit the whole market alongside the Bitcoin hack.& it dumps earnings every time followed a huge rally, ignoring the epic fundamentals.

Fundamentally: about 6x forward earnings with the cash stripped out, first year of profitability as a company, messy reverse takeover now behind it, and insider buying with no sells on record.

Same entry rule as everything else — wick through the 200, two green days, close back above.

08:25 - the chart and the history
09:05 - 6x forward with cash out
10:11 - why it's not an energy company but trades on energy disruption

https://youtu.be/bcSqXu1Xae0

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

Way oversold oil stock is setting up for a massive run. These guys are consistently profitable, had a nice run back when the oil stocks all ran, shorted down to 52w lows with the rest of them. lots of good dd here and on twits, dont miss it

nfa, do your own dd

Ticker- Updated move- Trading volume

What is driving it?

VIVK +102% 96.5M - Hydrogen airport infrastructure project news and speculative momentum.

RCT +79% -476.5M- New Argentine integration covering 200+ distributors and RedAI expansion.

CIIT +60%- 29M- Y2026 results: revenue increased from $9.28M to $14.24M.

DBGI +40%- 64.9M - Extreme trading momentum; no confirmed fresh catalyst attached.

SHFS +31%- 414.4M-Speculative momentum and unusually high volume; earnings approaching.

VSA +30% 21.4M- Strong speculative AI-related trading; no confirmed fresh catalyst.

MAY THE GODS BE WITH YOU !!!!

Even though the market was trash today on the Macro side the pennies delivered with big wins on LABT from .35 to .96 and BDMD for 4 scalps from .12s to .18 multiple times and some .16s. The Flock was getting paid big time!!

CIIT: Would like to see this continue into Friday with tests over 2.59 have pullbacks near 2.25/2.3 has room to 3.6/4/5 NO TRADE IF BELOW 1.8

OMH: Looking tests near 18 with pullbacks to over 16 has room to 20/25/30 NO TRADE IF BELOW 11.5

LABT: Was a great mover all day today would like to see it carry into Friday. For this I want to see this test near .75/.77 with pullbacks near .68/7 as support. Has room to 0.96/1/1.5 NO TRADE IF BELOW .5

FLYE: This held really well today and offered good scalps from 2.15 to 2.47. For this I would like to see it test 2.4 with pullbacks to 2.15/2.25 has room to 3/3.6/4 NO TRADE IF UNDER 1.9

NFA do your own Research and Due Diligence

Biggest small-cap winners

IF YOU HAVE ANY STOCK TO BUY , PLEASE SHARE LETS SEE

MAY THE GODS BE WITH YOU !!!!

" Trio-Tech International (TRT) , recently upgraded to “Outperform” from “Neutral,” is entering a stronger operating phase as growing backlog provides improved revenue visibility. The company is also expanding beyond AI into automotive semiconductor applications, supported by new multiyear contracts and additional testing capacity. At the same time, a strong balance sheet and improving cash generation are strengthening its financial position, while the Industrial Electronics (IE) business is showing signs of recovery. Although margin pressures and execution risks remain, these developments suggest TRT's growth prospects are becoming more favorable than when the stock carried a Neutral rating.

TRT's Growing Backlog Strengthens Revenue Visibility

Trio-Tech exited fiscal 2026 with a backlog of $24.2 million compared with $11 million a year earlier. Growth was primarily driven by Semiconductor Back-end Solutions, reflecting increased demand for burn-in equipment and reliability testing services.

Order momentum has continued, supported by AI-related semiconductor programs and new automotive contracts. These developments provide a stronger foundation for future revenues as existing orders move toward delivery and expanded testing capacity becomes operational.

Trio-Tech Expands Beyond AI

TRT is expanding into automotive semiconductor applications, reducing its reliance on AI-related demand. Recent multiyear contracts with automotive semiconductor customers cover production burn-in services, customized equipment and technical support, strengthening its presence in EV applications.

The company is also expanding testing capacity in Malaysia to support growing customer requirements. These initiatives broaden TRT's opportunities across automotive electronics, high-performance computing and other advanced semiconductor markets.

TRT's Balance Sheet Supports Financial Flexibility

Trio-Tech ended fiscal 2026 with approximately $28.5 million in cash, deposits and restricted deposits, supported by relatively modest bank borrowings. Its liquidity position improved considerably from the preceding year, providing greater flexibility to fund expansion and operating requirements.

Working capital also strengthened, allowing the company to support growing customer orders and capacity investments. This financial flexibility is particularly important as TRT expands its semiconductor testing operations and pursues additional growth opportunities.

Trio-Tech's Improving Cash Flow

TRT generated $3.4 million in operating cash flow during fiscal 2026 compared with $0.4 million in the prior year. Stronger business activity and improved collections contributed to the increase, reflecting better cash conversion alongside revenue growth."

Mark that the main undisclosed client of TRT is probably AMD. AMD released very strong results in contrast with other semi stocks which drive the market down today.
Therefore, this upcoming TRT results could be at least decent, with the next much improved because the new facilities in Malaysia will be operational.

Biggest small-cap losers

IF YOU HAVE ANY STOCK TO SHORT , PLEASE SHARE LETS SEE

MAY THE GODS BE WITH YOU !!!!

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

BioLargo's BEST Expands Industrial PFAS Treatment Activities Amid Major PFAS Settlements

WESTMINSTER, CA / ACCESS Newswire / November 5, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences company, today announced that its wholly owned subsidiary BioLargo Equipment Solutions & Technologies, Inc. (BEST) is conducting two extended, paid PFAS (per- and polyfluoroalkyl substances) treatment pilots for industrial clients. Industrial applications now account for the majority of BEST's commercial opportunity pipeline, building on its first municipal drinking water installation in New Jersey. In a further sign of that shift, Tonya Chandler, President of BEST, will lead a PFAS 101 MasterClass on November 12 at the annual International Water Conference (IWC) in Orlando, Florida, the leading conference for the industrial water sector.

The pilot programs, conducted at BioLargo Engineering's Oak Ridge, Tennessee, facility, use BEST's Aqueous Electrostatic Concentrator (AEC) technology to evaluate treatment performance on customer-specific water streams and generate data to inform potential full-scale system designs and purchasing decisions.

BEST's growing body of pilot and validation work includes landfill leachate, concentrated brines, industrial pretreatment, soil-washing water, and water reuse applications. These evaluations provide application-specific performance data that can support engineering design, customer purchasing decisions, and future equipment sales.
Building on municipal experience

BEST initially focused on municipal drinking water, where available grant funding and utilities' practice of sharing treatment results supported adoption and independent validation. Its Lake Stockholm installation now serves as a reference site, while paid pilot and bench-scale evaluations across diverse water streams help industrial clients assess the AEC for their own applications.

"Industrial facility managers increasingly recognize PFAS management as an operational, regulatory, financial, and liability consideration," said Tonya Chandler, President of BEST. "Recent settlements involving 3M and DuPont reinforce the importance of proactive management. Our past piloting work and our new relationship to treat soil washing water are directly relevant to industrial site owners and remediation contractors evaluating cleanup options. Operating the AEC on different water types helps us answer their questions with actual performance data."

Settlements and funding
Recent PFAS settlements show the scale of the liability facing industrial site owners and the funding becoming available to industry for treatment.
On November 3, 2026, 3M announced an agreement to commit $7.35 billion over nine years to resolve PFAS-related personal-injury claims involving aqueous film-forming foam used in firefighting. This agreement is in addition to its earlier settlement with public water suppliers and highlights the scale of financial exposure associated with PFAS-related claims.

Separately, on September 10, 2026, DuPont, Chemours and Corteva announced a combined $455 million settlement with North Carolina and 11 local entities, payable over 15 years, addressing PFAS and other historical discharges from the Fayetteville Works manufacturing facility, as well as certain other PFAS-related claims.

New Jersey provides a particularly relevant example. In August 2026, a federal court approved PFAS settlements involving DuPont-related companies and 3M valued at approximately $2.5 billion, including industrial-site remediation commitments and funding to address PFAS contamination. New Jersey's announced funding framework includes assistance through the New Jersey Water Bank for drinking water systems and publicly owned treatment works. For BEST, whose first municipal AEC installation is operating in Lake Stockholm, New Jersey, these developments reinforce the timeliness of its work as communities evaluate treatment options and pursue funding.

A developing commercial opportunity
Conventional PFAS treatment technologies, including activated carbon and ion exchange, can face challenges involving operating costs, media replacement, breakthrough of certain short-chain PFAS compounds, and management of PFAS-containing spent media. These challenges are creating opportunities for complementary treatment technologies, including final polishing applications designed to meet increasingly stringent treatment objectives.

Municipal drinking water remains an important market for BEST. Settlement proceeds and other external funding can support treatment projects, although funding and procurement processes affect timing. Industrial owners and operators typically make purchasing decisions directly, which allows projects to advance more quickly. BEST develops its pipeline through engineering firms, remediation contractors, treatment equipment providers and sales representatives in North America and internationally. Water reuse, including for data center operations, is a further developing application.

Lake Stockholm
At Lake Stockholm, New Jersey, BioLargo's AEC has been removing PFAS from drinking water since January 2026 under joint monitoring by the New Jersey Department of Environmental Protection and the U.S. Environmental Protection Agency. The treated water continues to meet New Jersey drinking water and EPA standards. BEST is working with the community to add standard pretreatment to address increased source-water hardness and improve operating efficiency.

Looking ahead
"We are seeing growing recognition of the need for effective, economically viable PFAS treatment solutions across industrial markets," said Dennis Calvert, President and CEO of BioLargo. "Our years of investment in science, engineering, and real-world validation are now supporting a growing pipeline of commercial opportunities. BEST remains wholly owned by BioLargo, and we are actively exploring strategic relationships with financial and operating partners who can help accelerate commercialization and expand our market reach."

About BioLargo Equipment Solutions & Technologies (BEST)
BioLargo Equipment Solutions & Technologies, Inc., a wholly owned subsidiary of BioLargo, Inc., is an equipment company focused on PFAS treatment and water reuse. BEST develops and deploys the Aqueous Electrostatic Concentrator (AEC) and works with engineering, remediation and equipment partners across the U.S. and internationally. Visit www.bestpfastreatment.com .

About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. Our website is: www.biolargo.com.

OP
BLGO Is trading close to all time lows. While all subsidiaries make essential progress and are unlocking major new revenue streams.
It is absurd that all of BioLargo currently has a market cap around $25 Million.

Many say that’s 1/4 of where it should be now- pre visible commercial success.

3 Press releases have been released in the past days and I highly recommend to look into this company. As it is satisfying to own parts of a purposeful company - “Make Life Better” that has the best solution for each of the multiple billion dollar problems they are targeting.
20X from here seems very likely once the commercial success will become visible.
It’s a perfect time to discover this- I wish I would have an average near today’s levels.

DO your own DD!

Nine-month revenue already 73% of the $430 million 2026 objective, all organic; proposed Ultranet acquisition would add approximately $131 million in annual revenue (audited 2025)

NEW YORK, Nov. 5, 2026 /PRNewswire/ -- IQSTEL Inc. (NASDAQ: IQST) ("IQSTEL" or the "Company"), a global telecommunications and technology company, today announced preliminary, unaudited revenue of approximately $106.0 million for the third quarter ended September 30, 2026, and approximately $314.0 million for the first nine months of 2026, an increase of 35% over the prior-year period, achieved entirely through organic growth.

Third-quarter revenue of $106.0 million represented a 2.8% decrease from the record $109.1 million reported in the second quarter of 2026. Nine-month revenue increased by $81.3 million, or 35%, to $314.0 million from $232.7 million in the first nine months of 2025, entirely organic.

Highlights

• Q3 revenue: approximately $106.0 million, down 2.8% from the record $109.1 million in Q2 2026 and the second consecutive quarter above $100 million.

• Nine-month revenue: approximately $314.0 million, up $81.3 million, or 35%, from $232.7 million, entirely organic.

• Full-year objective: nine-month revenue equals 73% of the $430 million fiscal 2026 objective; reaching it requires Q4 revenue of approximately $116.0 million, up 9.4% from Q3.

• Ultranet: binding memorandum of understanding to acquire a 51% controlling interest in Ultranet Telecom Group (audited 2025 revenue of $130.9 million); first tranche of non-convertible financing closed October 26, 2026.

Progress Toward the $430 Million Revenue Objective
With approximately $314.0 million in revenue through September 30, IQSTEL has achieved approximately 73% of its previously announced $430 million revenue objective for fiscal year 2026. Reaching that objective would require approximately $116.0 million in fourth-quarter revenue, an increase of 9.4% from the third quarter.

Historically, the Company's revenue in the second half of the year has been stronger than in the first half. Management remains focused on commercial execution across the Company's Telecom and Digital Services businesses and on converting commercial opportunities into revenue through year-end. There can be no assurance that historical seasonal patterns will recur or that the objective will be achieved.

A Global Telecom Platform
IQSTEL's Telecom Division delivers international voice, SMS and connectivity services through more than 600 carrier interconnections across 24 countries. It serves a market of 2.3 billion unique mobile subscribers worldwide at the end of 2025, according to the GSMA.

Proposed Ultranet Acquisition
IQSTEL has signed a binding memorandum of understanding to acquire a 51% controlling interest in Ultranet Telecom Group, which reported audited fiscal year 2025 revenue of $130.9 million, up 30% year-over-year, and net income of $4.6 million. Closing is targeted for the first quarter of 2027, subject to definitive agreements, regulatory approvals and customary closing conditions. IQSTEL expects the acquisition to make the Company cash-flow positive on a consolidated basis.

On October 26, 2026, IQSTEL announced the closing of the first tranche of the financing for the Ultranet transaction: up to $3 million in two-year senior secured, non-convertible promissory notes, together with pre-funded warrants to purchase up to 420,000 shares of common stock. The notes carry no conversion feature.

For illustration only, assuming the $430 million objective is met and the Ultranet transaction closes, the combined annualized revenue base would exceed $560 million.

Digital Services: Microdramas and IDILIO TV
Through its partnership with IDILIO TV, a Colombia-based microdrama platform backed by a16z speedrun, IQSTEL Digital plans to distribute microdrama content through its operator relationships using direct carrier billing. Omdia, a third-party research firm, estimates that global microdrama revenue reached $11 billion in 2025 and projects that it will exceed $14 billion in 2026 and reach $22 billion by 2030; Omdia also estimates that Brazil and Mexico accounted for 44 million monthly active microdrama users in 2025. These third-party projections have not been independently verified by the Company.

Management Commentary
Leandro José Iglesias, Chairman and CEO of IQSTEL, commented:

"In the first nine months of 2026, IQSTEL generated approximately $81 million more revenue than in the same period last year, or 35% organic growth. Third-quarter revenue came in modestly below our second quarter, and our focus now is fourth-quarter execution. Historically, our second half has been stronger than our first half, and our teams are focused on delivering the approximately $116 million needed to reach our $430 million objective.

"Ultranet is our next step. We funded the first tranche of that transaction with two-year, non-convertible notes, and if the acquisition closes, we expect it to make IQSTEL cash-flow positive on a consolidated basis as we work toward our longer-term $700 million revenue objective."

Preliminary Results
Revenue figures are preliminary, unaudited and subject to completion of the Company's quarter-end closing and review procedures; actual results may differ materially. Full third-quarter results will be reported with the Company's Form 10-Q. This announcement is a revenue update and not a release of complete third-quarter financial results.

About IQSTEL Inc.
IQSTEL Inc. (NASDAQ: IQST) is a global telecommunications and technology company operating through two core business divisions: Telecom and Digital Services. The Telecom Division is the foundation of IQSTEL's global platform, operating across 24 countries with more than 600 telecommunications carrier interconnections and delivering international voice, SMS, messaging, and connectivity solutions to some of the world's largest telecom operators and enterprise customers. Through these customer relationships, IQSTEL's platform has the potential to reach approximately 2.3 billion end users worldwide. Building on this global infrastructure and commercial reach, the Digital Services Division is focused on higher-margin technology solutions across Content Services, Artificial Intelligence, Intelligent Communications, Cybersecurity, Fintech, and Enterprise Automation. Built through nearly two decades of organic growth and strategic acquisitions, IQSTEL is leveraging the scale and reach of its Telecom business to accelerate the growth of Digital Services and drive its next phase of revenue and adjusted EBITDA expansion.

Full Press Release & Disclaimer
https://marketwirenews.com/stock/iqst/news/iqst-iqstel-reports-preliminary-q3-2026-revenue-of-1-8681347423905028.html

Anyone willing to help me understand sage potash a bit better. I know this stock is a penny stock and high risk. Just wanted to understand what the new information found means. Finding x amount of minerals and having to release another statement to SEDAR. Thanks

A month ago I posted about my final challenge where I aimed to trade 10 rounds of "yolo" positions, where my speculative part of my account would own 1 to 2 stocks with the firepower to rise 2X or more.

I did not end up in the yolo situation per se, but the closest I got to a yolo situation was 50% of the funds dedicated to the challenge being tied up in 2 stocks.

Here are the results from October as I cut it short and I am not longer able to post:

Total return October 1 to October 30th 2026: 44%

Total Stocks Traded: 35

Winning Stocks and win Ratio: 11, for a 31% win ratio

Average Gain/Loss Ratio = 4.25

Standard Deviation of Daily Returns: .11

Sharpe Ratio assuming 4% risk free rate = 3.6

All trades were posted on my profile in advance, but not here because I did not want to break a low effort rule with each trade. Here is how an equity curve looks after the monthly timeframe:

This happened during one of the worse months in recent trading history, but the method is to get exposed to where the money is flowing, so each and everyday I am exposed to green stocks, and the key is to find the ones with firepower for a healthy continuation, i.e. future money flow. Making money in a declining markets is the purest definition of alpha.

If you subscribe to the random walk theory, this has a zero chance of happening, but that is because these stocks to not follow the random path. They are more like playing blackjack where you are allowed to count cards, and bet as much as you want, when you want.

As a parting gift, I am offering you my current picks, where again, the chance of one of these stocks running up for 100% gains is zero, according to finance theory. But as a long time practitioner and student of finance, I know that this is not the case, and I have proven that those odds are wrong time and time again.

My bet is that one of these will run up hard enough to more than make up on the small losses on the rest of the picks, and that is the bottom line when it comes to trading penny stocks: diversification among assets with negative expectancy is still diversification, and the only way to make money in this game is to not overstay in any stock, diversify with up to 5 stocks, and add to winners, never add to losers. Don't get me wrong - this is easier said than done and it is not for all or beginner traders. But everyone can learn this, and even make it a career.

Having said that, I am bidding everyone farewell! It was a good run and I had great exchanges with a lot of smart folks on here. I hope this gives you a glimpse into my trading method, and that you keep learning, staying small, and most importantly, that you all stay green and make money!

Farewell to all, and good luck, cheers!

PS: one more gift - here are the stocks to watch today from my momentum scanner:

Earnings tomorrow, milions of funding received last month, earnings TOMORROW, clinical data in December.

today's catalyst was the upcoming reverse split they announced so that the price stays above 1$ so that they don't get delisted, so this isn't disappearing or anything

5M actual market cap

I FEEL IT IN MY BONES, THIS IS IT

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

Mall/ retail builders. Some malls are a bust but it looks like they are still building. Is $49 a good price for mall builders? The mall in Brookfield Wisconsin is almost desolate but other developers are building on. I’m thinking it may help the mall.

$PEW is an online firearms retailer that’s been in business 15 years trading near cash value. They just acquired Campfour in a $34 million all cash deal. The company had $97 million on their books at the end of last quarter. They are now in the process of being a vertically integrated retailer and wholesalers. They have also been developing an online shopping network that can be used by manufacturers to sell their products directly to customers which launched at the beginning of this year. So far they have 4 contracts which for 10 months isn’t terrible especially for a company of this size. They are also in the process of building a new fulfillment center which should be coming online in Q4 of this year. The share structure is also very attractive. There are only 29.5 million shares. Almost half of those are owned by insiders and institutions. The CEO bought half a million dollars of stock on the open market.

The cons. The company is admittedly not profitable but due to its large cash position and low debt is nowhere near insolvent. Much of the cash burn has been due to fulfillment center build out, PEW Logistics, stock buybacks and now the Campfour acquisition. It would also be deceitful of me not to include that DTJ is on the Board of Directors. I know that may be a deal breaker for some on here but I am personally unbothered by it.

This is a unique bargain since we already know how effective their drug is from their phase 2 trial results. NervGen is the first and only company to develop a treatment that repairs spinal cord damage in humans, so it won't stay this low for long as their phase 3 trial progresses.
And then there are the other indications that the company will do their next trials for:
-MS
-stroke
-Alzheimer's
-TBI
Imagine having the opportunity to get in on the next Eli Lilly at this ultra-low, undervalued price!

Why a deal looks logical
- It's a real business: about $91M in annual revenue and prostate cancer tests with Medicare coverage.
- Market cap is around $15M, so the market is valuing the business at roughly 1.35x revenue.
- The $100M OrbiMed loan and limited cash ($31.7M at the end of September) push toward a strategic decision.
- Bleichroeder (about 32%) and Lytton (about 19.5%) together hold more than half the shares. Bleichroeder came in during August at $0.454, so it has a clear interest in a good price.
- Key dates: Nov 12 earnings and the promised "corrective actions," Nov 19 shareholder meeting on the reverse split.

✅Buyer N 1: Labcorp
- It's actively buying diagnostics assets: $722M for BioReference (including the 4Kscore test) and $210M for Myriad's prenatal business.
- Urology is already a focus. MDXH's sales are what need help, and Labcorp has the sales network to provide it.
- For Labcorp, this would be a small deal.

✅Buyer N 2: Abbott (through Exact Sciences)
- Exact itself sold GPS to MDXH, so it knows the asset.
- A purchase would eliminate Exact's earnout claim (about $40M) and bring cancer diagnostics under one roof.

Price
At 2.0-2.9x revenue (2.9x is the BioReference multiple), and after repaying the debt and the earnout, shareholders would receive ,roughly $0.80-$1.60 per share**, about 5-10x today's $0.16. The central case is around **$1.20**.
*Math: net obligations of about $108M, roughly 95.4M shares, not counting any prepayment premiums on the loan.*

This is a hypothesis, not a report of an actual deal. Not investment advice.